Clinical Cases in Advanced Prostate Cancer

Jorge A. Garcia, MD, FACP, describes the case of a 57-year-old African American man with nonmetastatic castration-resistant prostate cancer, and Ganesh V Raj, MD, PhD, reviews how the MRI/TRUS fusion biopsy is becoming a mainstay in diagnosis.

Experts in genitourinary oncology share their use of novel imaging in practice for nonmetastatic castration-resistant prostate cancer.

Ganesh V Raj, MD, PhD, shares his approach to radiation therapy in patients with nonmetastatic castration-resistant prostate cancer.

Mary-Ellen Taplin, MD, reviews the criteria used to initiate androgen deprivation therapy in the setting of rising PSA syndrome for patients with nonmetastatic castration-resistant prostate cancer.

Ganesh V Raj, MD, PhD, and Mary-Ellen Taplin, MD, review the role of next-generation sequencing in nonmetastatic castration-resistant prostate cancer, and who qualifies based on NCCN guidelines.

Experts in genitourinary oncology share their methods and patient specific factors that aid in selecting therapy for nonmetastatic castration-resistant prostate cancer.

Experts in genitourinary oncology share how they decide between the 3 antiandrogen therapies for nonmetastatic castration-resistant prostate cancer: apalutamide, enzalutamide, and darolutamide.

Experts in genitourinary oncology discuss how they choose therapy for patients with long PSA doubling times in nonmetastatic castration-resistant prostate cancer (nmCRPC).

Ganesh V Raj, MD, PhD, presents data from the phase 3 SPARTAN trial of apalutamide for nonmetastatic castration-resistant prostate cancer (nmCRPC).

Patrick G. Pilié, MD, presents data from the phase 3 PROSPER trial of enzalutamide, and Ganesh V Raj, MD, PhD, presents data from the phase 3 ARAMIS trial of darolutamide for nonmetastatic castration-resistant prostate cancer (nmCRPC).

Jorge A. Garcia, MD, FA, describes the case of a 72-year-old man with metastatic castration-resistant prostate cancer.

Experts in genitourinary oncology review the treatment choices available after metastatic castration-resistant prostate cancer progression on abiraterone acetate + prednisone.

Mary-Ellen Taplin, MD, shares her method for selecting and dosing chemotherapy for metastatic castration-resistant prostate cancer.

Patrick G. Pilié, MD, presents data from the phase 3 CARD trial of cabazitaxel in metastatic castration-resistant prostate cancer.

Mary-Ellen Taplin, MD, presents data from the phase 3 PROfound trial of olaparib in metastatic castration-resistant prostate cancer.

Mary-Ellen Taplin, MD, presents data from the phase 2 TRITON2 trial of rucaparib in metastatic castration-resistant prostate cancer.

Experts in genitourinary oncology share their excitement for promising emerging agents and combination therapies for advanced prostate cancer in the coming years.